Allurion Technologies, Inc.

Allurion’s Allurion Program products are currently sold across Europe, the Middle East, Africa, Latin America, Canada, and the Asia-Pacific region, reflecting a primarily international commercial footprint. The company has launched the Virtual Care Suite (VCS) in the United States for patients utilizing other weight-loss treatments, while it has submitted a premarket application to the FDA for approval to sell the Allurion Program in the U.S. Geographic mix matters because order timing, available selling days (including holidays), and foreign currency movements can drive quarter-to-quarter variability in reported results and margins. The multi-region model also increases exposure to differing regulatory regimes and the operational complexity of supporting distributors and providers across markets.

Allurion’s growth is highly sensitive to market acceptance by healthcare providers, since demand depends on provider awareness, confidence, and willingness to adopt the Allurion Program in routine practice. Regulatory risk is central: the company must obtain and maintain approvals across markets, execute any required remediation to resume sales where applicable, and successfully navigate the FDA PMA process to commercialize the Allurion Program in the U.S. Operationally, sales performance depends on the size and ramp of the sales force and distributor execution, while product and geographic mix and foreign exchange can create volatility in quarterly results. The company has also undertaken restructuring and workforce reductions, which may not deliver expected savings and could disrupt R&D, clinical activities, cybersecurity posture, and compliance capabilities. As a medical device and digital health business, it also faces product liability, clinical evidence expectations, reimbursement/affordability dynamics, and competitive pressure from pharmacologic anti-obesity therapies and bariatric procedures.